TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02171104
Drug: IMD Preparative Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan
Study: NCT02171104
Drug: Osteopetrosis Only Preparative Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa
Study: NCT02171104
Drug: Osteopetrosis Haploidentical Only Preparative Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine
Study: NCT02171104
Drug: cALD SR-A (Standard-Risk, Regimen A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine start day +1 through day +28
Study: NCT02171104
Drug: cALD SR-B (Standard-Risk, Regimen B)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine start day +1through day +56
Study: NCT02171104
Drug: cALD HR-D (High-Risk, Regimen C)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
Study: NCT02171104
Drug: cALD HR-D (High-Risk, Regimen D)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
Study: NCT02899000
Drug: Oral doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
Study: NCT01307046
Drug: MK-0954A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
Study: NCT02832544
Drug: Vitamin K antagonists (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
Study: NCT04367831
Drug: Heparin Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
Study: NCT04367831
Drug: Heparin SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
Study: NCT03789916
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg die
Study: NCT02448797
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
Study: NCT03785704
Drug: Xinmailong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
Study: NCT02263508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intratumoral injection
Study: NCT03373149
Drug: Growth hormone/HPuFSH/GnRH antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Study: NCT02108106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01266265
Drug: inhaled prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyvaso
Study: NCT03373149
Drug: HPuFSH/GnRH antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Study: NCT00825188
Drug: eplerenone, amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
Study: NCT00825188
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 25-50mg daily x 8 weeks
Study: NCT00825188
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eplerenone 25- 50 mg daily for 8 weeks
Study: NCT01266265
Drug: oral ERA
Normalized name: ALCOHOL 4 mL TOPICAL CLOTH [Bioserica ERA Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by physician
Study: NCT00210782
Drug: topiramate, phenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01796782
Drug: QYHJ Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-4 bags bid , days 1-42, every 6 weeks
Study: NCT01191892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of vandetanib tablet
Study: NCT02477670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03546907
Drug: SAR440340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: SC
Study: NCT03546907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: SC
Study: NCT03546907
Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
Study: NCT00228007
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02139046
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets
Study: NCT01779232
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered daily like the active comparator
Study: NCT00381004
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
Study: NCT02965248
Drug: Standard adjuvant systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.
Study: NCT00062179
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
Study: NCT03110458
Drug: SENS-111 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
Study: NCT00723307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White coated tablet; one tablet twice daily; 1.5 years duration
Study: NCT03110458
Drug: SENS-111 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
Study: NCT03110458
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
Study: NCT01131078
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
Study: NCT00711126
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mcg IV
Study: NCT00711126
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mcg oral
Study: NCT02040298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily
Study: NCT03002805
Drug: CBT-1®
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed.
Study: NCT02451917
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
Study: NCT02300363
Drug: Treatment A (rosuvastatin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin administered on Day 1 and Day 13
Study: NCT02300363
Drug: Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
Study: NCT00228358
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01724866
Drug: SPI-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-2012 SC injection.
Study: NCT01724866
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide given based on standard dose for chemotherapy.
Study: NCT05688761
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term use of medications, particularly proton pump inhibitors
Study: NCT03812003
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
Study: NCT00111722
Drug: Comparator: placebo / Duration of Treatment - 1 day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02623868
Drug: CKD-519 50mg 2Tabs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.
Study: NCT02623868
Drug: CKD-519 100mg 1Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.
Study: NCT02623868
Drug: CKD-519 100mg 1Cap.
Approvals — FDA: no, EMA: no, PMDA: no
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.
Study: NCT01456936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dummy placebo for each treatment arm
Study: NCT01173601
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01173601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01773486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching hesperidin
Study: NCT04737278
Drug: Cunermuspir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide
Study: NCT00217425
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion per institutional guidelines.
Study: NCT00217425
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
Study: NCT03951077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally
Study: NCT01473732
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
Study: NCT02748785
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be continued
Study: NCT01221662
Drug: Siwu Tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Siwu Tang 3 g bid(oral) continuously two weeks
Study: NCT00854685
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0mg/kg s.c. - weekly
Study: NCT00854685
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0mg/kg s.c. - fortnightly
Study: NCT05590650
Drug: SZKJT(San-Zhong-Kui-Jian-Tang)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
Study: NCT00854685
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg/kg s.c. - weekly
Study: NCT00854685
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg/kg s.c. - fortnightly
Study: NCT00854685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c. - weekly
Study: NCT00854685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c. - fortnightly
Study: NCT01080807
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Study: NCT02222558
Drug: TSX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSX-002 are capsules with testosterone as the active ingredient.
Study: NCT02987751
Drug: Glargine + Glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
Study: NCT00896298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT02836652
Drug: acetylsalicylic acid (ASA) therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (81mg/day)
Study: NCT00481702
Drug: MK0826, /Duration of Treatment : 8 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05757648
Drug: Non-buffered Anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-buffered LA, 2% lidocaine with epinephrine 1:100,000
Study: NCT05757648
Drug: Buffered Anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
Study: NCT02248805
Drug: MGD007
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
Study: NCT02071199
Drug: 1X ACCS (Amnion-derived Cellular Cytokine Solution)
Normalized name: liver derivative complex Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
Study: NCT02071199
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
Study: NCT02071199
Drug: 0.3X ACCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
Study: NCT03708718
Drug: Prednisolone 5 mg
Normalized name: prednisolone 5 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg prednisolone, once a day for 6 months
Study: NCT03708718
Drug: Placebo oral capsule; From August 2020 'no additional treatment'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
Study: NCT03741972
Drug: iSGTL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Study: NCT01648634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
Study: NCT04353830
Drug: IBI939
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
Study: NCT01581736
Drug: U100 Humulin
Normalized name: Humulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
Study: NCT02246816
Drug: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Study: NCT05888675
Drug: Weifuchun
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
Study: NCT01948999
Drug: Anesthesia
Normalized name: anesthesia tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary induced state of analgesia
Study: NCT03280017
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion
Study: NCT01250366
Drug: Placebo matching with INX-08189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, Once daily, 7 days
Study: NCT00617604
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and subcutaneous injection
Study: NCT01434134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, target dose 100 mg once daily
Study: NCT01434134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 32 mg once daily
Study: NCT00876161
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
Study: NCT00876161
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no